Cupid Ltd Q1 FY2023 Concall Summary

Key Takeaways

• Soft quarter, strong order book: Female condom sales dipped on lab delays and container shortages, but the overall order book stood at a robust Rs. 187 Crores, dominated by repeat UNFPA and private orders.
• USFDA application is the big swing factor: A marketing application for female condoms was filed, with approval possible in six to nine months; management sees a minimum \$2–\$3 million first-year US opportunity, which would transform the top and bottom line.
• IVD vertical is now live, but nascent: Six manufacturing licenses were obtained and commercial activity began in July; early outreach is underway across Africa and India, though a material order book is still months away.
• Full-year guidance implies a sharp recovery: Management expects Rs. 145 Crores turnover and Rs. 20–25 Crores PAT for FY23, betting on a female condom catch-up, a new jelly run-rate, and initial IVD contributions to close the gap.
• What to watch next quarter: The pace of female condom order recovery, any early IVD order book build, and whether the potential company sale progresses beyond evaluation.

Female Condom: The Quarter’s Drag and the US Catalyst

• Q1 headwinds were operational, not demand-driven: Sales were lower because of delayed lab results and non-availability of containers; a depreciating South African Rand further reduced order frequency from that key market.
• Catch-up planned across remaining quarters: Management intends to recover the shortfall over the next three quarters and is maintaining a minimum FY23 sales target of Rs. 30 Crores for the segment.
• USFDA application filed, outcome binary and high-impact: A three-month pregnancy study in South Africa enabled the marketing application; if approved, Cupid would be only the second female condom company in the US market.
• First-year US ambition is material relative to current scale: Management projects a minimum \$2–\$3 million in first-year US revenue, distributed through both over-the-counter and prescription channels, with market margins better than 50% on sales.
• Approval timeline is uncertain: The process may take six to nine months or longer depending on USFDA workload, pushing any material US revenue into FY24.

Om Garg: "In US, we are planning to distribute our products through over-the-counter sales as well as through prescription businesses and the market margins would be better than 50% on the sale, and right now, we do not have a precise estimate, but we are looking at a minimum of \$2 to \$3 million business in the first year."

IVD: A New Vertical in Early Motion

• Licensing milestone achieved: Six manufacturing licenses for In-Vitro Diagnostics kits were obtained from the Drug Controller of India during the quarter, clearing the path for domestic and export marketing.
• Commercial activity just began: Marketing efforts started in July, with brochures and samples circulated to major African countries including South Africa, Kenya, Mozambique, Nigeria, and the DRC.
• Early distribution interest is building: A technical conference in Chennai generated contact with 190 distributors, doctors, and clinical labs; a Singapore party with five patented diagnostic products is exploring an outsourcing partnership and plans a Nasik facility visit in August.
• A serious Oman enquiry is in play: One of the largest pharma companies in Oman wants to be a lead distributor for all products and is planning a Nasik visit later in the month.
• Revenue and order book are too early to size: The current IVD order book is only a few lakhs, and management says it will be at least three more months before a significant number can be reported; minimum FY23 sales are pegged at Rs. 5 Crores with no precise estimate yet.
• Branding strategy is dual-track: Products will be marketed under Cupid’s own brands with separate brand names for each product, while outsourcing arrangements will use the customer’s brand; the company is open to domestic outsourcing as well.

Order Book & Financial Position

• Order book provides near-term visibility: The Rs. 187 Crores order book as of July 1, 2022, is composed largely of repeat orders from UNFPA and other private customers, with new orders arriving regularly.
• Cash position has strengthened: Cash stood at Rs. 84 Crores as of July 1, an improvement both sequentially and year-on-year.
• No buyback, working capital takes priority: After consulting with an advisor, management decided against a buyback this year because combined working capital needs for the condom and IVD businesses could reach Rs. 30–40 Crores; action will be taken at the appropriate time.
• Capacity expansion is on hold: No immediate CapEx plans exist for this year or next, following last year’s male condom capacity expansion from 40 crore to 56 crore pieces per year and the entry into the IVD vertical.
• Male condom utilization was high at 88% in Q1, while female condom utilization dropped to 82% because production was much lower.

Jelly/Lubricant Business

• Performance has improved and the segment now carries margins of 40% to 45%.
• FY23 revenue target is Rs. 10–15 Crores, adding a steady, higher-margin stream to the product mix.

Corporate Developments

• Greenmate Corporation shares surrendered: Shares held by the original South Korean investor, which went bankrupt roughly 10 years ago, were surrendered into a government education fund per SEBI rules after an eight-year lapse.
• Potential acquisition or sale still unresolved: Discussions are ongoing with one potential buyer who is evaluating future prospects and valuation, but no final decision has been communicated back to the company.

Guidance & Commitments

Om Garg: "We are expecting a turnover of about Rs.145 Crores and a profit after tax of about Rs.20 Crores to Rs.25 Crores for the entire FY2023. So, we are hoping for a big improvement in our performance going forward as compared to a year ago."

Key Metrics